Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.215
-0.040 (-1.77%)
Feb 9, 2026, 11:15 AM EST - Market open
BDTX Employees
Black Diamond Therapeutics had 24 employees as of December 31, 2024. The number of employees decreased by 30 or -55.56% compared to the previous year.
Employees
24
Change (1Y)
-30
Growth (1Y)
-55.56%
Revenue / Employee
$2,916,667
Profits / Employee
$895,750
Market Cap
126.20M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 24 | -30 | -55.56% |
| Dec 31, 2023 | 54 | -11 | -16.92% |
| Dec 31, 2022 | 65 | -21 | -24.42% |
| Dec 31, 2021 | 86 | 17 | 24.64% |
| Dec 31, 2020 | 69 | 37 | 115.63% |
| Sep 30, 2020 | 58 | 28 | 93.33% |
| Jun 30, 2020 | 49 | 28 | 133.33% |
| Mar 31, 2020 | 37 | 16 | 76.19% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 188 |
| Fate Therapeutics | 181 |
| Sutro Biopharma | 178 |
| Cibus | 159 |
| Adagene | 138 |
| Seres Therapeutics | 103 |
| Korro Bio | 87 |
| Connect Biopharma Holdings | 62 |
BDTX News
- 2 months ago - Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Benzinga
- 2 months ago - Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM - GlobeNewsWire
- 2 months ago - Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - GlobeNewsWire
- 2 months ago - Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout - Seeking Alpha
- 3 months ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
- 6 months ago - Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash - Seeking Alpha